Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 362 participants.
Also called NCT05832931
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 362 participants
- Sponsor
- Pathalys Pharma
- Registry
-
NCT05832931 -
2023-504338-24
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Bulgaria, Poland, Portugal, Serbia, Spain
- Registry status
- Completed
Technical summary
Registry record NCT05832931. Randomized; triple masking; primary purpose treatment. Start 2023-04-28 (actual); primary completion 2025-07-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1
- Acronym
- PATH-1
- Condition
- Secondary Hyperparathyroidism
- Condition
- End-stage Kidney Disease (ESKD)
- Intervention (Drug)
- PLS240
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Open-Label Extension PLS240
- Lead sponsor
- Pathalys Pharma
- Collaborator
- Launch Therapeutics
Record details
- Record id
cardio:ct-nct05832931- Content hash
f935ceb30144b1358e28d9c98cd0b6ead2faf7f44d1bf215447acd6bfdd5e9a8